NO973963L - Fremgangsmåte for å hemme ovariecancer - Google Patents
Fremgangsmåte for å hemme ovariecancerInfo
- Publication number
- NO973963L NO973963L NO973963A NO973963A NO973963L NO 973963 L NO973963 L NO 973963L NO 973963 A NO973963 A NO 973963A NO 973963 A NO973963 A NO 973963A NO 973963 L NO973963 L NO 973963L
- Authority
- NO
- Norway
- Prior art keywords
- ovarian cancer
- steps
- inhibiting ovarian
- inhibit ovarian
- vidcreforincsdna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39595195A | 1995-02-28 | 1995-02-28 | |
| PCT/US1996/002621 WO1996026727A1 (en) | 1995-02-28 | 1996-02-27 | Methods of inhibiting ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO973963D0 NO973963D0 (no) | 1997-08-28 |
| NO973963L true NO973963L (no) | 1997-08-28 |
Family
ID=23565226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO973963A NO973963L (no) | 1995-02-28 | 1997-08-28 | Fremgangsmåte for å hemme ovariecancer |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0729755A2 (enExample) |
| JP (1) | JPH11501033A (enExample) |
| KR (1) | KR19980702553A (enExample) |
| CN (1) | CN1176600A (enExample) |
| AU (1) | AU5028696A (enExample) |
| CA (1) | CA2214080A1 (enExample) |
| EA (1) | EA199700200A1 (enExample) |
| FI (1) | FI973521A7 (enExample) |
| HU (1) | HUP9801327A3 (enExample) |
| IL (1) | IL117277A0 (enExample) |
| NO (1) | NO973963L (enExample) |
| WO (1) | WO1996026727A1 (enExample) |
| ZA (1) | ZA961564B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5886025A (en) * | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| FR2873692B1 (fr) * | 2004-07-29 | 2006-12-01 | Univ Claude Bernard Lyon | COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA |
| CN103432141A (zh) * | 2013-08-29 | 2013-12-11 | 南京大学 | Chukrasone A在治疗卵巢癌药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| DE3590389T1 (de) * | 1984-08-02 | 1986-08-28 | Schering Corp., Kenilworth, N.J. | Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| CZ253694A3 (en) * | 1993-10-15 | 1995-05-17 | Lilly Co Eli | Pharmaceutical preparation for treating resistant neoplasms |
| IL115582A0 (en) * | 1994-10-14 | 1996-01-19 | Lilly Co Eli | Methods for treating resistant tumors |
-
1996
- 1996-02-26 ZA ZA9601564A patent/ZA961564B/xx unknown
- 1996-02-27 JP JP8526378A patent/JPH11501033A/ja active Pending
- 1996-02-27 EP EP96301306A patent/EP0729755A2/en not_active Withdrawn
- 1996-02-27 CA CA002214080A patent/CA2214080A1/en not_active Abandoned
- 1996-02-27 CN CN96192239A patent/CN1176600A/zh active Pending
- 1996-02-27 EA EA199700200A patent/EA199700200A1/ru unknown
- 1996-02-27 FI FI973521A patent/FI973521A7/fi unknown
- 1996-02-27 AU AU50286/96A patent/AU5028696A/en not_active Abandoned
- 1996-02-27 WO PCT/US1996/002621 patent/WO1996026727A1/en not_active Ceased
- 1996-02-27 HU HU9801327A patent/HUP9801327A3/hu unknown
- 1996-02-27 IL IL11727796A patent/IL117277A0/xx unknown
- 1996-02-28 KR KR1019970705959A patent/KR19980702553A/ko not_active Withdrawn
-
1997
- 1997-08-28 NO NO973963A patent/NO973963L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0729755A3 (enExample) | 1996-09-11 |
| EA199700200A1 (ru) | 1998-02-26 |
| CN1176600A (zh) | 1998-03-18 |
| JPH11501033A (ja) | 1999-01-26 |
| FI973521L (fi) | 1997-08-27 |
| ZA961564B (en) | 1997-08-27 |
| AU5028696A (en) | 1996-09-18 |
| WO1996026727A1 (en) | 1996-09-06 |
| HUP9801327A3 (en) | 1999-10-28 |
| FI973521A0 (fi) | 1997-08-27 |
| FI973521A7 (fi) | 1997-08-27 |
| NO973963D0 (no) | 1997-08-28 |
| IL117277A0 (en) | 1996-06-18 |
| KR19980702553A (ko) | 1998-07-15 |
| MX9706520A (es) | 1997-11-29 |
| EP0729755A2 (en) | 1996-09-04 |
| CA2214080A1 (en) | 1996-09-06 |
| HUP9801327A2 (hu) | 1999-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO973635L (no) | Fremgangsmåte for hemming av celle-celle adhesjon | |
| NO944928L (no) | Fremgangsmåter for inhibering av Alzheimers sykdom | |
| NO971520L (no) | Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y | |
| IL111288A (en) | Uses of 2-phenyl-3-aroylbenzothiophenes and 3-phenyl-4-aroyl-1,2-dihydronaphthalenes for the preparation of a medicament for inhibiting smooth muscle cell proliferation and restinosis | |
| IL111284A (en) | 2-phenyl-3-aroylbenzothiophenes for use as medicaments for inhibiting endometriosis | |
| NO944919L (no) | Fremgangsmåte for å inhibere atrofi av huden eller vagina | |
| NO944927L (no) | Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom | |
| NO944914L (no) | Fremgangsmåte for å inhibere autoimmunsykdommer | |
| MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
| IL115014A0 (en) | Methods of inhibiting viral replication | |
| NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
| NO944926L (no) | Fremgangsmåter for å inhibere myeloperoksidaseaktivitet | |
| NO944924L (no) | Fremgangsmåter for inhibering av Turner's syndrom | |
| DK0652004T3 (da) | Fremgangsmåder til behandling af resistente neoplasmer | |
| NO975580L (no) | Fremgangsmåte for å inhibere melanom | |
| NO973367L (no) | Fremgangsmåte for å inhibere miljömessige östrogen | |
| NO973609L (no) | Fremgangsmåte for å inhibere effektene av IL-6 | |
| NO981578L (no) | FremgangsmÕte for hemming av plasminogenaktivatorhemmer I | |
| NO971794L (no) | Fremgangsmåte for hemming av tilstander forbundet med bradykinin | |
| MX9701333A (es) | Metodos para inhibir el daño neuronal. | |
| NO973103L (no) | Fremgangsmåte for inhibering av veksthormoneffekter | |
| NO971029L (no) | Fremgangsmåter for hemming av endometriale metoser | |
| NO20000750L (no) | FremgangsmÕte for Õ redusere blodplatetall | |
| NO970783L (no) | Fremgangsmåte for å hindre endometrialkreft | |
| NO944909L (no) | Fremgangsmåter for inhibering av mannlig infertilitet |